Friday, August 12, 2011
Lexicon Pharmaceuticals Inc., of The Woodlands, Texas, published Phase II data showing LX1031 was well tolerated and provided relief from pain and discomfort in non-constipating irritable bowel syndrome. The data were published in Gastroenterology. LX1031 is a tryptophan hydroxylase inhibitor.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.